← Back to Team

Mike Ross

Managing Partner

Michael rossa banner
$asset->title

Mike joined SV Health Investors as a Venture Partner in 2001 and became Managing Partner in 2002. He is responsible for biotech investments and activities in the US and serves on the boards of companies in the US and UK.

His career spans over 19 years in venture capital, which followed 21 years in senior operating executive roles for leading biotechnology companies.

At SV, Mike has been involved from the beginning with the Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee. He has been the seed investor in a number of startup biotech companies and has invested in platform companies, small molecule, antibody and cell therapy therapeutic companies.

Prior to joining SV, Mike was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha-Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. He then started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Mike was also the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Viacyte).

Outside of SV, Mike serves on the Board of the Thayer School of Engineering (Dartmouth College). Mike enjoys tennis, boating, photography and hiking.

Academic credentials
AB, Dartmouth College; PhD, Chemistry, Caltech; NIH Post-Doctoral Fellowship, Molecular Biology, Harvard

Portfolio